BioSpace News Archive

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer.

RayzeBio, Inc. appointed Mary Tagliaferri, M.D. to its board of directors effective September 29, 2021.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2021 financial results before the market opens on Thursday, October 21, 2021.

Mosaic ImmunoEngineering Inc. today announced that Nicole F. Steinmetz, Ph.D., acting chief scientific officer and co-founder of Mosaic and the director of the UC San Diego Center for Nano-ImmunoEngineering, delivered a Spotlight Presentation at the World Molecular Imaging Congress (WMIC) on Friday, October 8, 2021.

Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to “reprogram” patient immune cells using the Company’s patent pending “ex vivo cell-free” reprogramming protocol.

Arcturus Therapeutics Holdings Inc. today announced that the Vietnam Ministry of Health has approved initiation of the Phase 3b part of the placebo-controlled, observer-blind Phase 1/2/3 clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern.

The IMA Group (IMA) announced today the acquisition of Diagnostics Research Group (DXRG), a clinical research site in San Antonio, Texas, with expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies, and pulmonary and fatty liver diseases.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today provided an update on the progress of its development programs, ADAIR and ADMIR, which leverage the Company’s proprietary technology that is designed to resist manipulation for snorting and provide barriers to injection.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021 financial results and provide a general business update.